Takeda Reports Results for the First Half of FY2015Confirms Management Guidance for the Full Year
30.10.2015 06:00 | Business Wire
Takeda Pharmaceutical Company Limited (TOKYO:4502):
First half results aligned with management guidance
- Underlying revenue +3.8% year-to-year (reported revenue growing +6.2% to 904 billion yen)
- Underlying Core Earnings +3.7% year-to-year (operating profit -5.4% to 110.4 billion yen)
Continued performance of Takeda's strategic growth drivers in the first half
- Gastroenterology underlying revenue +28.7%, oncology up +1.6% year-to-year
- Emerging markets underlying revenue +7.1% year-to-year, with particularly strong contributions from Russia and China
- Consolidated underlying revenue of gastroenterology, oncology and emerging markets – Takeda's growth drivers – is +10.0% year-to-year
First half growth supported by innovative new products
- Entyvio success continues to support more than $2 billion peak sales target
- Brintellix and Adcetris show steady growth
- Azilva and Lotriga continue to grow strongly in Japan
- Year-to-year underlying revenue growth in U.S. +12.0% (driven by Entyvio and Brintellix), Europe and Canada +1.5% (Entyvio and Adcetris), and emerging markets +7.1% (Russia and China)
- Strong growth of new products in Japan. Underlying revenue in Japan decreased by 3.4% year-to-year as a result of increasing generic penetration
Efficiency gains continue
- Project Summit achieved 11 billion yen of cost savings in the first half of FY2015
- On track to deliver more than 20 billion yen savings this fiscal year
Affirming management guidance for profitable growth in FY2015
- Low single-digit underlying revenue growth in FY2015, with underlying core earnings growth higher than underlying revenue growth, and underlying core EPS growth higher than underlying core earnings growth
Christophe Weber, President and Chief Executive Officer of Takeda, commented:
"In the first half of FY2015, Takeda continued its turnaround with underlying revenue growth of 3.8%, led by our growth drivers of gastroenterology, oncology and emerging markets. Operating profit was down in the first half of the year, mainly due to an increase in expenses for several recent launches and in R&D, as planned, but underlying core earnings increased by 3.7%, getting closer to underlying revenue growth. On the basis of our first-half results, we confirm our full-year management guidance."
Key figures for H1 of FY2015
|FY 2014||FY 2015||Growth|
|Core Earnings 1||169.9||177.5||+4.5%||+3.7%|
|Net Profit 3||61.4||54.4||-11.5%||–|
|EPS||78 yen||69 yen||-11.2%||–|
|Core EPS||134 yen||135 yen||+1.2%||+7.9%|
1 Core Earnings is calculated from operating profit by
excluding the impact of exceptional items, such as purchase accounting,
amortization and impairment loss of intangible assets, restructuring
costs and litigation costs.
2 Underlying performance aims at understanding the real performance of the business. Underlying Revenue and Underlying Core Earnings excludes the same as above and adjusted for acquisitions/divestments and foreign exchange.
3 Attributable to the owners of the company
Underlying revenue growth in the first half was +3.8%, Underlying Core Earnings was +3.7% and Underlying Core EPS was +7.9%, with no changes in our management guidance for FY2015. Reported revenue grew +6.2% to 904.0 billion yen. An increase in expenses for new launch products, as well as a decrease in other income related to sale of real estate in 2014, resulted in a year-to-year decline in Operating Profit, Net Profit and EPS, by 6.2 billion yen, 7.1 billion yen and 9 yen, respectively. These measures have improved in the second quarter compared to the first quarter.
Underlying revenue growth was mainly driven by Takeda's growth drivers, which are gastroenterology, oncology and emerging markets. Gastroenterology grew by +28.7% year-to-year, driven by Entyvio. Oncology revenue, including Velcade and Adcetris, increased by +1.6%. Emerging markets revenue grew by +7.1%, led by Value Brands (branded generics and OTC), with strong growth in Russia and China. Performance in the U.S. (+12.0% underlying revenue growth) and Europe and Canada (+1.5%) also contributed to revenue growth. In Japan, products such as Azilva and Lotriga contributed to revenue growth, but as a result of increasing generic competition, total revenue declined -3.4%.
Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 11 billion yen savings in the first half. Execution of Summit initiatives in recent months include business restructuring programs, further optimization of production capacity utilization, and continued operational efficiency. A new global procurement organization also contributed by leveraging effective external spending. Efficiency initiatives as part of Project Summit remain on track, and Takeda is committed to continued operational efficiency.
Entyvio is expected to be a key global contributor to Takeda's sales growth over the next few years, and Azilva, Lotriga, and Takecab are the products that are expected to enable Takeda to maintain a leading position in Japan. As part of the ongoing efforts of the R&D organization, ixazomib for relapsed/refractory multiple myeloma was granted accelerated assessment status in Europe in July, and Priority Review status in the U.S. in September 2015. In Japan, Takeda submitted a New Drug Application for the fixed-dose combination tablet of Nesina and metformin, and received approval for Leuplin 24 week depot for the treatment of prostate cancer and premenopausal breast cancer and for Copaxone for the treatment of multiple sclerosis in September 2015.
Takeda confirmed its management guidance for FY2015, leading to long-term sales and profit growth.
Management Guidance for FY2015
|Underlying Revenue||Low single digit|
|Underlying Core Earnings||Higher than underlying revenue growth|
|Underlying Core EPS||Higher than underlying core earnings growth|
For more details on Takeda’s FY2015 H1 results and other financial information please visit http://www.takeda.com/investor-information/results/
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Takeda Pharmaceutical Company Limited
Noriko Higuchi, +81-(0)3-3278-2306
Tsuyoshi Tada, +81 (0)3-3278-2417
English media and media outside Japan
Tobias Cottmann, +41-79-217-7252
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ANA Announces New Online Content "IS JAPAN COOL? DOU"23.8.2017 15:00 | Pressemelding
Today, All Nippon Airways Co., Ltd. (ANA), Japan’s largest and only 5-Star airline, is proud to announce the launch of its new online content “IS JAPAN COOL? DOU,” which illustrates traditional Japanese culture through the use of cutting-edge technology. This content can be seen on “IS JAPAN COOL?,” a website that promotes tourist destinations and popular Japanese cultures to the world. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005024/en/ "IS JAPAN COOL? DOU" TOP (Graphic: Business Wire) While Japan is widely known for its unique pop culture, “IS JAPAN COOL?,” which launched in 2012, has put much of its focus on promoting Japan’s modern culture. As the number of tourists visiting Japan exceeded 24 million people as of 2016, the project aims to provide a deeper understa
Emailage Receives $10 Million Growth Equity Investment to Accelerate Global Expansion23.8.2017 14:00 | Pressemelding
Emailage, the leading provider of global fraud prevention and identity verification using email address scoring, today announced that it has received a $10 million growth equity investment. Anthos Capital led the investment, with participation from Radian Capital, Wipro Ventures, Mucker Capital and Tallwave Capital. Emailage will use the funding to expand existing partnerships, further advance its powerful email address-based predictive scoring system, and accelerate growth in North America, EMEA, LATAM and other key markets. “This investment will allow us to continue our rapid growth, enhance our leadership position in the online fraud detection market and deliver significant fraud prevention capabilities to businesses around the world,” said Emailage CEO Rei Carvalho. Emailage’s Software-as-a-Service solution delivers powerful, real-time risk intelligence by leveraging the
Westinghouse to Provide Fuel to PSEG’s Salem Nuclear Generating Station Through Continued Partnership23.8.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has signed a nuclear fuel contract extension with PSEG, a major supplier of nuclear power in New Jersey, to continue providing fuel assemblies for both units at the Salem Nuclear Generating Station. “Westinghouse has been the single-source fuel provider for PSEG’s Salem plant since its start of operations more than 40 years ago, and we are pleased to continue to support this important and long-standing customer through the delivery of safe, reliable high-performance fuel,” said David Howell, president, Americas Region, and chief growth officer at Westinghouse. “This continued partnership is recognition of our reliable fuel performance and confirmation of the important trust PSEG has in Westinghouse.” Under the terms of the contract, Westinghouse will deliver its 17x17 Robust Fuel Assemblies, known as RFA-2. The design of
GN Hearing Announces Availability of Rechargeable Solution for the Recently Launched ReSound LiNX 3D23.8.2017 12:00 | Pressemelding
GN Hearing introduces a rechargeable battery option for the revolutionary ReSound LiNX 3D hearing aids. Available in North America and other major markets from September 1, the rechargeable battery solution gives ReSound users even more options to choose from. The rechargeable option is also available for Beltone Trust in North America, and from September 1 this will be extended to other major markets. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005211/en/ GN Hearing has made a rechargeable battery option available for the revolutionary ReSound LiNX 3D hearing aids. (Photo: Business Wire) ReSound LiNX 3D Rechargeable – More Than Just Another Rechargeable Hearing Aid The rechargeable battery option is made available based on a deep understanding of user expectations
EURid Supports Uganda Borehole Rehabilitation Project23.8.2017 09:00 | Pressemelding
EURid has announced its support to the Borehole Rehabilitation project in Uganda to provide thousands of people with clean drinkable water. EURid sees water as the most basic requirement for life. For many rural communities across Sub-Saharan Africa it is still a struggle to find safe drinking water. Moreover, water drawn from rivers could potentially contain lethal contaminants and therefore must be boiled before ingestion, adding yet an additional hardship for families as well as the environment in terms of firewood used. The goal of the Borehole Rehabilitation project is to better this situation by working with Ugandan communities to repair broken boreholes and restore access to clean, safe drinking water. The direct benefits of the project are that families no longer have to travel great distances to attain water or boil the water to eradicate contaminants, saving firewood and prev
His Highness Sheikh Mohammed bin Rashid Al Maktoum Unveils Blueprint for Dubai Food Park23.8.2017 07:00 | Pressemelding
His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has unveiled the blueprint for Dubai Food Park (DFP), the latest addition to Dubai Wholesale City (DWSC). This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005041/en/ Central Wholesale Market within Dubai Food Park (Photo: AETOS Wire) To be developed at a cost of US$1.5 billion, first destination in the Middle East dedicated to serving the food sector. DFP seeks to enhance Dubai’s position as a leading regional hub for food trade, import, export and re-export of foodstuffs. Conceptualized at a time when food trade makes up 11 percent of the UAE’s GDP and the food industry is estimated to grow by 70 percent to US$6.3 billion by 2030, the Park will offer all categories of f
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom